Investment Rating - The report indicates a strong investment rating for the Emerging Tech sector, particularly in AI and healthcare, with record capital deployment in 2025 [6][16]. Core Insights - Top investors are significantly increasing their investments, with ETI funding reaching $33.1 billion across 874 deals in 2025, marking a record despite lower deal counts compared to previous years [6][16]. - AI investments are at an all-time high, with 51.6% of ETI deals in Q4 2025 directed towards AI startups, surpassing the broader venture space [6][50]. - The trend towards larger deal sizes is evident, with rounds exceeding $50 million and $100 million becoming more common, reflecting a shift in investor strategy towards fewer, higher-value bets [6][17]. Deal Activity - In Q4 2025, top investors participated in 225 seed and early-stage deals totaling $10.5 billion, matching previous quarterly peaks despite lower transaction volumes [16]. - The concentration of funding in megadeals is notable, with three companies raising $2 billion each, capturing 18% of all ETI capital [17]. - The median deal sizes for ETI startups are significantly higher than the broader VC market, with pre-seed/seed median deal sizes at 3.3 times the overall VC median [18][19]. Areas of Investment - AI/ML remains the dominant segment, capturing $5.3 billion across 53 deals in Q4 2025, with significant activity in vertical applications such as fintech and healthtech [23][49]. - Healthtech & wellness saw a substantial increase in activity, reaching $678 million across 23 deals, driven by consumer healthcare technologies and AI-enabled solutions [66]. - Cybersecurity investments surged to $643.1 million in Q4 2025, with a focus on AI-native platforms due to the rise of AI-powered threats [79]. Notable Activity - The fintech sector recorded $682.8 million across 24 deals in Q4 2025, with significant investments in AI-native platforms [107]. - The largest non-AI ETI round was Tempo's $500 million Series A for a blockchain platform, highlighting continued interest in innovative financial technologies [108]. - Biotechnology is showing signs of recovery, with 10 deals in Q4 2025, reflecting renewed investor interest in high-value, clinical-stage assets [87].

Investment Rating - The report indicates a positive outlook for the healthtech industry, emphasizing substantial opportunities across all nine healthtech segments driven by AI advancements [11]. Core Insights - The healthcare delivery and administration landscape is expected to be fundamentally reimagined, with AI playing a crucial role in alleviating clinical and administrative burdens, leading to significant ROI [11]. - The order of preference for investment segments in healthtech is as follows: 1) digital care & treatments, 2) operations, 3) revenue cycle, 4) analytics, 5) care management, 6) electronic health records and clinical information, 7) infrastructure & compliance, and 8) sport & wellness [11]. Healthtech Landscape - The healthtech ecosystem includes various segments such as telehealth, care management, sport & wellness, analytics, revenue cycle, infrastructure & compliance, and electronic health records [6]. VC Activity - Healthtech startups raised $3.8 billion in VC funding during Q4 2025, slightly below the previous three quarters but 131.7% above the same quarter last year [12]. - Total VC funding for healthtech in 2025 reached $15.3 billion, a 26.1% increase from 2024 [13]. - Notable Q4 deals included Ōura's $907.7 million Series E funding and OpenEvidence's $200 million round [12][31]. Valuations - The median pre-money valuation for healthtech VC reached $31 million in 2025, up from $26.5 million in 2024, reflecting rising valuations driven by AI [14]. - Early-stage VC valuations averaged $50 million, 82.8% above the prior three-year average [14]. Exit Activity - VC exits surged to an all-time high of 141 in 2025, although total exit value remained steady at $5.8 billion [15]. - IPO momentum improved with five listings in 2025, including notable companies like Omada Health and Hinge Health [16]. AI Investment Dominance - AI continues to dominate healthtech investment allocation, influencing administrative efficiencies and clinical operations workflows [17]. - The clinical documentation category alone saw $1.2 billion in deal funding in 2025, highlighting the significant investment in AI-driven solutions [18]. Funding Relative to Prior Averages - Practice management companies experienced the greatest relative gains in 2025 at 392% of the prior three-year average, followed by clinical documentation at 381% [20].

Core Viewpoint - Glow Holdings, Inc. has launched a new corporate website to enhance its digital presence and provide stakeholders with access to corporate information and updates on its developments in the healthtech sector [1][3]. Group 1: Company Overview - Glow Holdings, Inc., operating as GlohCo, is focused on developing AI-powered software and data-driven tools for mental health, behavioral health, and social determinants of health [4]. - The company aims to serve various stakeholders, including hospitals, insurance companies, treatment centers, and behavioral health organizations [2]. Group 2: Website Launch and Purpose - The new website serves as a central digital presence for investors, shareholders, and stakeholders, offering access to corporate information, leadership details, press releases, and investor relations materials [1]. - The website is expected to be updated regularly as the company achieves new milestones in platform development, partnerships, and corporate governance [3]. Group 3: Industry Engagement - Following a corporate transition announcement in January 2026, the company has engaged with the behavioral health sector, reaching out to clinicians, treatment center operators, and multi-state providers in South Florida [2].

Core Viewpoint - Premier Health of America Inc. has reported a significant decline in revenues and gross margin for the first quarter ended December 31, 2025, compared to the same period in 2024, while focusing on cost reduction and operational efficiency [2][3][4]. Financial Performance - Revenues for the first quarter were CAD 17.835 million, down from CAD 32.132 million in the same quarter of 2024, representing a decrease of approximately 44.4% [2]. - Gross margin decreased to CAD 2.726 million, with a gross margin percentage of 15.28%, compared to CAD 5.137 million and 16.0% in the previous year [2]. - Adjusted EBITDA fell to CAD 5, down from CAD 705,000 in the same period last year, indicating a significant decline in operational profitability [2][8]. - The net loss for the quarter was CAD 2.549 million, compared to a net loss of CAD 2.261 million in the same quarter of 2024 [2][8]. Operational Highlights - The travel nurse and northern communities services are performing well overall, except for a decline in British Columbia due to a service acquisition centralization initiative by health authorities [3]. - The company has formally discontinued its Per Diem and Transportation operations, reallocating resources to focus on Travel Nurse operations across Canada [3][4]. - The interim CEO emphasized ongoing efforts in cost reduction, debt management, and operational efficiency, with a commitment to pursuing organic growth opportunities [4]. Company Overview - Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of outsourced healthcare services to governments, companies, and individuals [6]. - The company utilizes its proprietary LiPHe platform to drive digital transformation in the healthcare services sector, aiming to provide faster, more affordable, and accessible care [6].

Masimo Founder Joe Kiani On The Healthtech Company’s $10 Billion Acquisition https://t.co/twE5qYVHnH (📸: Ethan Pines for Forbes) https://t.co/LPKl8nJPaO ...

Core Viewpoint - Auddia Inc. is set to merge with Thramann Holdings, forming a new holding company named McCarthy Finney, with a new ticker symbol MCFN, and Auddia shareholders will own approximately 20% of the new entity at closing [1][4][6]. Company Overview - Auddia Inc. operates in the audio technology sector, focusing on reinventing consumer engagement with audio content through its proprietary AI platform [10]. - Thramann Holdings is a privately held company that controls three early-stage AI-native companies: LT350, Influence Healthcare, and Voyex, founded by Jeff Thramann, who has extensive experience in securing patents and taking companies public [2][3]. Merger Details - The merger agreement has been unanimously approved by the boards of both companies and is expected to close in the second quarter of 2026, subject to customary closing conditions [6]. - Upon completion, Auddia will be renamed McCarthy Finney, and Jeff Thramann will continue as CEO, with John Mahoney as CFO [3][4]. Financial Valuation - The base case discounted cash flow (DCF) valuation of McCarthy Finney is estimated to be $250 million, based on a forward-looking 10-year pro forma analysis [5]. - Auddia must have at least $12 million in cash on hand at closing to ensure a cash runway for future business milestones [4]. Ownership Structure - At the closing of the merger, Auddia shareholders are expected to own 20% of McCarthy Finney, while Jeff Thramann will own 80% [4].

Group 1 - Glow Holdings, Inc. has introduced its GlohCo health intelligence platform, focusing on the mental and behavioral health sector [1][2] - The company is expanding its operational footprint to South Florida, recognizing it as a key hub for behavioral health due to the concentration of treatment providers [3] - The U.S. behavioral health market is estimated to exceed $90 billion annually, with significant underserved segments identified, particularly among multi-state treatment operators and substance use disorder providers [4] Group 2 - GlohCo is being developed as a predictive, AI-driven health intelligence platform aimed at supporting clinical and operational decision-making in care delivery [5] - The platform will operate on a subscription-based model, generating revenue through software and platform services [6] - The company is currently preparing its 2025 financial statements and anticipates value creation through pilot programs and signed enterprise customers [6]

Core Insights - Premier Health of America Inc. has filed its Audited Annual Consolidated Financial Statements and MD&A for the year ended September 30, 2025, indicating a challenging financial performance with significant net losses and a decline in revenues compared to the previous year [1][2]. Financial Performance - For Q4 2025, revenues were CAD 20.79 million, down from CAD 33.46 million in Q4 2024, representing a decrease of approximately 37.9% [2]. - The gross margin for Q4 2025 was CAD 3.45 million, with a gross margin percentage of 16.6%, slightly up from 15.9% in Q4 2024 [2]. - Adjusted EBITDA for Q4 2025 was CAD 440,000, a decline from CAD 995,000 in the same period of 2024 [2][9]. - The net loss for Q4 2025 was CAD 6.5 million, compared to a loss of CAD 2.3 million in Q4 2024, indicating a worsening financial situation [2][9]. Segment Performance - The Per Diem segment, impacted by Quebec's Bill 10, represented less than 1% of Q4 revenue and less than 4% of total revenues for the year, leading to its abandonment in Q1 2026 [3]. - Travel nurse and northern communities' services performed well overall, except in British Columbia, where a volume reduction was noted due to centralization efforts by health authorities [4]. - The company is reorganizing its Quebec operations, reducing workforce and corporate structure to achieve cost savings, with a reduction in salary expenses by CAD 0.7 million in Q4 2025 compared to Q4 2024 [5][6]. Strategic Focus - The company is shifting its focus entirely to Travel Nurses after abandoning the Per Diem segment and is exploring opportunities in the Home Care sector [6]. - Cost reduction, debt management, and operational efficiency remain priorities, alongside pursuing organic growth opportunities [6].

Core Viewpoint - Glow Holdings, Inc. has transitioned into a healthtech-focused public company following a corporate reset completed in 2025, introducing its proprietary GlohCo health intelligence platform with an initial focus on mental and behavioral health [1][5] Company Overview - GlohCo aims to leverage data, analytics, and emerging technologies to provide modern care organizations with insights into workflows, risk, and outcomes, supporting decision-making in digital health and care delivery environments [2] - The company had limited operations prior to 2025 and underwent a custodianship and change of control, resulting in new ownership and a strategic reset [3] Strategic Developments - In late October 2025, Glow Holdings, Inc. acquired an operating healthcare staffing business, which provided active industry operations and recurring service revenue, establishing a foundation for near-term business activity [4] - Management views the staffing operations as an enabling layer that supports platform development through exposure to real-world workflows and operational environments [4] Leadership Perspective - The President of Glow Holdings, Inc. emphasized the priority of restoring compliance and establishing a solid foundation for the company, with ongoing efforts to build the GlohCo platform focused on healthtech intelligence and data-informed tools [5]

As filed with the Securities and Exchange Commission on December 10, 2025 Registration No. 333- 290302 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (I.R.S. Employer Identification Number) (State or Other Jurisdiction of Incorporation or Organization) Classification ...